AMN Healthcare delivered the kind of quarter that resets a narrative. It also requires careful reading. Adjusted EPS of $1.16 beat the $0.22 consensus by 274.2% and cleared the $0.31 Earnings Whisper number by a wide margin. Earnings grew 197.4% year over year. Revenue of $717.27 million topped the $648.01 million consensus by 10.7%, rose 13.0% from a year ago, and landed roughly 10% above the top of management's own $640-655 million guide. GAAP EPS was $0.83, up from $0.76. That is the central tension: the headline beat was heavily assisted by labor-disruption work and a reserve release, yet the core nurse and allied staffing engine underneath it is accelerating in a way that skeptics were not positioned for.

The quality of the beat deserves scrutiny. Labor-disruption revenue reached $59 million, up from $25 million in Q2 and $12 million a year ago. That figure included a $51 million favorable reserve adjustment tied to prior strike events. Consolidated gross margin of 31.9%, up 280 basis points year over year and 130 basis points sequentially, was explicitly driven by that release. The call analysis indicates that, excluding it, gross margin sat at the low end of guidance and adjusted EBITDA was near the low end. Excluding strike activity, consolidated revenue grew about 6%. The 13.0% adjusted EBITDA margin and the sequential jump in adjusted EPS from $0.77 should therefore not be treated as a run rate. Cash flow also moved the wrong way: operating cash flow was negative $88 million as AMN refunded most of its strike-related client deposits, and cash fell to $256 million.

The operating story is genuinely better. Travel nurse volume growth accelerated from 6% year over year in Q2 to 21% in Q3, and allied growth improved from 7% to 12%. Nurse and allied revenue excluding strikes rose 15%, ahead of the 9-11% framing given last quarter. Average travelers on assignment climbed to 9,486, up from 8,203 a year ago, and rose 3% sequentially despite normal seasonality. Management said demand is up about 70% from the February low through October. It also pointed to early signs of bill-rate firming, including clinicians holding out for better offers, guaranteed work weeks, and rapid-response orders. Elsewhere, search grew 15%, and locum tenens revenue rose 6% sequentially with revenue per day filled improving. Locums remains down 5% year over year, however, and Technology and Workforce Solutions fell 9%.

The forward guide is where bears have legitimate ammunition. Q4 revenue guidance of $655-670 million sits above the prior quarter's guide, and nurse and allied revenue excluding strikes is expected to grow 13-15%. Total Q4 revenue, however, is projected to fall 10-12% year over year because labor-disruption revenue shrinks to about $5 million from $124 million. Profitability guidance is notably weak:

• gross margin of 25.7-26.2%, versus a 27-27.5% guide for Q3;
• adjusted EBITDA margin of 5.8-6.3%, versus 6.5-7.0% for Q3;
• operating margin of roughly breakeven.

Management expects locums margins to fall about 200 basis points and Technology and Workforce Solutions margins about 100 basis points. Bill rates have been flat for roughly 18 months. The international nurse outlook was cut for a third straight call because of embassy visa delays, and that business is now expected to decline sequentially in the low teens in Q4. The Kaiser contract also expires at year-end and is in a competitive RFP. On the positive side, leverage improved to 1.3x from 3.3x a year ago. Management also cited:

• a pipeline that is more than half managed-services opportunities;
• new vendor-management client wins onboarding for 2027;
• an expected recovery in language services margins toward about 40% as interpreter capacity ramps.

Investors had already moved ahead of the report. Sentiment shifted meaningfully, from slightly negative at -0.05 to a positive 0.29. Shares rose 50.7% from the open after the August report to $47.74, sitting about 65% above the 200-day moving average and just 3.8% below the 52-week high of $49.62 set October 27. The stock entered earnings near the top of its inter-earnings range, so the market setup is more complicated than the surprise implies. Much of the volume recovery was arguably anticipated, while the Q4 margin compression was not obviously priced. Earnings Whispers trend readings are mostly positive, though the sequential growth trend remains negative, consistent with a Q4 guide that steps down from Q3.

The bottom line is that AMN's quarter preserved a credible recovery story: travel nurse volume is accelerating, demand is broadening, and pricing may finally firm into 2027. The headline beat, however, was inflated by a one-time strike reserve release. Q4 guidance implies margins near breakeven at the operating line, and the international nurse business and Kaiser contract present real risks. With the stock near its highs and sentiment now positive, the next leg likely depends on whether bill-rate firming shows up in margins rather than just volume.